Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Acebutolol effects on lipid profile.

¹University of Alabama, Center for Aging, Birmingham 35294.

The American Journal of Cardiology

|September 25, 1990

Summary

Beta blockers like acebutolol may negatively impact lipid profiles, potentially increasing coronary artery disease risk. This study investigated effects of various antihypertensives on patient lipids.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A few kind words for the Devil.

Journal of religion and health·2014

Same author

Serine-204 in the linker region of Smad3 mediates the collagen-I response to TGF-β in a cell phenotype-specific manner.

Experimental cell research·2013

Same author

Estradiol enhances endothelial cell interactions with extracellular matrix proteins via an increase in integrin expression and function.

Angiogenesis·2003

Same author

Talking at cross purposes: molecular interactions downstream from TGF-beta.

Kidney international·2001

Same author

Risk factors for cardiovascular disease in children on maintenance dialysis.

Advances in renal replacement therapy·2001

Same author

Antithrombin III, protein S, and coagulation in the nephrotic syndrome.

Pediatric nephrology (Berlin, Germany)·2001

Area of Science:

Cardiology
Pharmacology
Hypertension Management

Background:

The link between lipid profiles and coronary artery disease (CAD) is well-established.
Certain antihypertensive medications, especially beta blockers without intrinsic sympathomimetic activity (ISA), may adversely affect lipid levels, potentially increasing CAD risk.

Purpose of the Study:

To evaluate the effects of different antihypertensive drug classes on lipid profiles in patients with mild hypertension.
To compare the lipid profile changes induced by acebutolol (a beta blocker with ISA) against other classes and placebo.

Main Methods:

A multicenter, randomized, controlled, double-blind study involving 847 patients with mild hypertension.
Patients received nonpharmacologic interventions plus one of five antihypertensive medications (acebutolol, amlodipine, chlorthalidone, doxazosin, enalapril) or placebo.
Lipid profiles, blood pressure, and target organ damage were monitored over one year.

Main Results:

Acebutolol significantly decreased total cholesterol (-12.7 mg/dl) and low-density lipoprotein (LDL) cholesterol (-6.0 mg/dl) compared to placebo and chlorthalidone.
No significant change in high-density lipoprotein (HDL) cholesterol was observed with acebutolol.
Chlorthalidone showed an increase in total cholesterol and LDL cholesterol compared to placebo.

Conclusions:

Acebutolol demonstrated a favorable effect on lipid profiles by reducing total and LDL cholesterol.
Findings suggest that not all beta blockers may negatively impact lipids, warranting further investigation into specific agents and their cardiovascular implications.

Related Experiment Videos